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Abstract 
The presence of circulating tumor cells (CTC) or microemboli (CTM) in the peripheral blood can 
theoretically anticipate malignancy of solid lesions in a variety of organs. We aimed to preliminarily 
assess this capability in patients with pulmonary lesions of suspected malignant nature.  
We used a cell-size filtration method (ScreenCell) and cytomorphometric criteria to detect 
CTC/CTM in a 3 mL sample of peripheral blood that was taken just before diagnostic 
percutaneous CT-guided fine needle aspiration (FNA) or core biopsy of the suspicious lung lesion. 
At least one CTC/CTM was found in 47 of 67 (70%) patients with final diagnoses of lung malignancy 
and in none of 8 patients with benign pulmonary nodules. In particular they were detected in 38 
(69%) of 55 primary lung cancers and in 9 (75%) of 12 lung metastases from extra-pulmonary 
cancers. Sensitivity of CTC/CTM presence for malignancy was 70.1% (95%CI: 56.9-83.1%), 
specificity 100%, positive predictive value 100% and negative predictive value 28.6% (95%CI: 
11.9-45.3%). Remarkably, the presence of CTC/CTM anticipated the diagnosis of primary lung 
cancer in 3 of 5 patients with non-diagnostic or inconclusive results of FNA or core biopsy, 
whereas CTC/CTM were not observed in 1 patient with sarcoidosis and 1 with 
amarthocondroma. 
These results suggest that presently, due to the low sensitivity, the search of CTC/CTM cannot 
replace CT guided percutaneous FNA or core biopsy in the diagnostic work-up of patients with 
suspicious malignant lung lesions. However, the high specificity may as yet indicate a role in cases 
with non-diagnostic or inconclusive FNA or core biopsy results that warrants to be further 
investigated. 
Key words: circulating tumor cells; lung nodule; lung cancer; lung metastases; CT-guided fine needle 
aspiration. 
Introduction 
The term “liquid biopsy” refers to the search and 
characterization in the peripheral blood of both 
circulating tumor cells (CTC) or microemboli (CTM) 
and biomolecules, such as free circulating DNA and 
micro-RNA [1]. “Liquid biopsy” is receiving growing 
attention in lung oncology because it can 
non-invasively and repeatedly provide valuable 








modulation according to a personalized medicine 
approach [2-4]. 
The presence of CTC or CTM can theoretically 
anticipate malignancy of solid lesions detected in a 
variety of organs and hence have a diagnostic value. 
So far, this possibility has been investigated in 
patients with breast, gastric, pancreatic and prostatic 
lesions [5-8]. Lung is one special organ as it frequently 
harbors primary or secondary cancer lesions. The 
differential diagnosis with a variety of benign lung 
lesions is a very common clinical problem that is 
usually addressed by percutaneous or transbronchial 
fine needle aspiration (FNA) or core biopsy [9,10]. 
In this study, we aimed to preliminarily 
determine the predictive value for malignancy of 
detection of CTC/CTM in patients with single or 
multiple suspicious pulmonary lesions. 
 
Patients and methods 
Patients selection 
This prospective study recruited 75 consecutive 
patients undergoing diagnostic percutaneous 
CT-guided FNA or core biopsy of pulmonary lesions 
of suspected malignant nature at the Diagnostic and 
Interventional Radiology Unit of the Careggi 
University Hospital of Florence, Italy. The study was 
approved by the Local Ethical Committee (decision 
May 18, 2015; protocol number BIO 15.009) and each 
patient provided a written consent to participate to 
the study. 
Eligible patients were those with single or 
multiple peripheral lung nodules or masses amenable 
of percutaneous CT-guided FNA or core biopsy for 
diagnostic purposes. We excluded patients who 
refused consent to blood sampling, those with a 
history in the last 5 years of pulmonary and 
extra-pulmonary malignancy or who had received 
chemo or radiation therapy. Moreover, to avoid the 
possibility of CTC delivery in the bloodstream as a 
result of tumor manipulation [11,12] we also excluded 
patients who had undergone diagnostic 
transbronchial FNA or core biopsy within 7 days 
before the percutaneous procedure. 
Blood sample collection 
In each patient, 7 mL of blood were collected in 
one 10 mL EDTA tube just before CT-guided FNA or 
core biopsy through the antecubital vein access 
routinely prepared before the procedure.  
Percutaneous CT-guided FNA and core biopsy 
Percutaneous CT-guided FNA biopsy of the 
target lung lesion was performed with a 25-23 gauge 
needle by one of four interventional radiologists on a 
40 rows of detectors Fluoro-CT scanner (Sensation 
Open, Siemens, Erlangen, Germany) dedicated to 
interventional procedures. FN aspirates were 
processed and analyzed by one of the two expert 
cytopathologists with Rapid On Site Examination 
(ROSE) [9,13] and cytological diagnosis was made 
according to the 2015 lung cancer classification [10]. 
Immunocytochemistry on FNA material for primary 
lung cancer was performed in 34 patients in whom 
typical morphological patterns for adenocarcinoma, 
squamous cell carcinoma or neuroendocrine tumors 
were not present. In particular on the FNA material, 
but not on the isolated CTC/CTM (see below), a 
limited panel of TTF1, P63 and CD56 markers to 
enable diagnosis of lung adenocarcinoma, squamous 
cell carcinoma or small cell carcinoma, respectively, 
was used. Moreover, in 5 patients we performed 
immunocytochemistry on FNA material to 
differentiate metastasis of colorectal cancer or breast 
cancer from primary lung cancer. We used a panel 
with TTF1, cytokeratin 7 and cytokeratin 20, estrogen 
and progesterone receptor for such a purpose.  
In 20 cases, FNA was supplemented by core 
biopsy performed with a 20-16 gauge needle and the 
latter was evaluated with routine histological 
procedures. 
CTC analysis 
Blood samples were processed within 3 hours 
after collection and CTC analysis was performed 
according to a standardized procedure reported in a 
previous study dealing with a different series of 
patients, selected because of advanced lung cancer 
[14]. For each patient, we prepared 2 filters 
corresponding to a 6 mL volume of blood. The second 
filter served as backup in case of technical failures due 
to filter contamination or incomplete filtration and 
was stained on demand. 
Isolation  
Blood was filtered by the ScreenCell Cyto 
filtration devices according to the procedure 
previously described [14, 15] that allows isolation by 
cell size and does not involve any biological 
characterization of the putative CTC. Before filtration 
and in order to lyse red blood cells, 3 mL of the blood 
sample were diluted in 4 mL of the proprietary 
dilution buffer, according to the manufacturer’s 
instructions (ScreenCell FC dilution buffer; 
ScreenCell). After blood filtration, an additional 1.6 
mL of PBS was filtered to remove red blood cell 
debris. Filtration was usually completed within 
approximately 3 minutes. The filter was then 
disassembled from the filtration module and allowed 
to air-dry.  





After an average of 10 days since FNA or core 
biopsy (range 7-21 days), the filters were evaluated in 
consensus by the same two expert cytopathologists 
(C.M. and M.Mat.) who had performed ROSE. They 
were blind to both the identity of the patient and the 
FNA or core biopsy results. 
Cytological assessment was conducted directly 
on the filter. The track-etched filters were stained with 
hematoxylin solution S (Merck KGaA), applied to the 
membrane for 2 minutes, and with Shandon eosin Y 
aqueous (Thermo Electron Corporation, Thermo 
Fisher Scientific Inc) for 30 seconds. For microscopic 
observation, the ScreenCell Cyto filter was placed on a 
standard microscopy glass slide, and a 7-mm circular 
cover slip (Menzel-Glaser) was laid on the filter with 
the appropriate mounting medium.  
CTC were identified among the cells retained on 
filter according to the presence of at least four of the 
following cytomorphological criteria: nucleus size ≥16 
μm, anisonucleosis (ratio > 0.5), high (>2:1) 
nuclear/cytoplasmic ratio, irregular nuclei and 
presence of three-dimensional sheets [14-16]. CTM 
were defined as clusters formed by >3 CTC [17]. 
Diagnostic work-up and staging 
Final diagnoses were based on the results of 
FNA or core biopsy. In case of non-diagnostic (due to 
insufficient material) or inconclusive (doubtful 
features) results of CT-guided FNA or core-biopsy, 
diagnosis was based on clinical, laboratory, CT 
follow-up data or surgical pathology results. 
The clinical or pathologic stage of ultimately 
diagnosed lung cancers was determined according to 
the 2009 Staging System [18]. 
Statistical analysis 
A basic statistical evaluation was performed 
with computation of sensitivity, specificity, positive 
predictive value (PPV) and negative predictive value 
(NPV) of CTC/CTM presence with regard to the final 
diagnosis of malignant or benign pulmonary lesion.  
Results 
The demographic data, the results of 
percutaneous CT-guided FNA or core biopsy, of the 
search of CTC/CTM, and the final diagnoses of the 
target lung lesions in the 75 patients are detailed in 
Table 1. Final diagnosis of primary lung cancer was 
made in 55 (23 stage I, 6 stage II, 9 stage III and 17 
stage IV) and of benign lung nodule in 8 patients. In 
particular, FNA or core biopsy demonstrated primary 
lung cancer in 55 patients (38 adenocarcinomas, 12 
squamous cell carcinomas, 1 not otherwise specified 
non small cell lung cancer, 1 small cell lung cancer, 2 
carcinoid tumors, 1 neuroendocrine tumor with 
malignant features), secondary lesions (1 urothelial, 3 
head and neck, 4 intestinal, 2 breast, 1 pancreas, 1 
neuroendocrine) in 12 patients and benign lesions in 8 
patients (3 amarthocondroma, 3 inflammation, 1 
abscess, 1 sarcoidosis). In particular, the percutaneous 
CT guided procedure was non-diagnostic in 4 patients 
and inconclusive in 1 (overall 5/75=6.7%). Surgical 
pathology and follow-up data established diagnosis 
of primary lung cancer (adenocarcinoma) in 3 cases 
and of sarcoidosis and amarthocondroma in 1 case 
each. 
Overall, in 18 patients it was necessary to stain 
and evaluate the second filter due to technical 
problems of incomplete filtration, presence of white 
blood elements and Candida albicans contamination 
that obscured possible CTC presence. 
Figure 1 graphically shows the results of 
CTC/CTM search and of FNA or core biopsy in the 75 
patients. At least one CTC/CTM in 3 mL of blood was 
found in 47 of 67 (70%) patients with final diagnoses 
of lung malignancy and in none of 8 patients with 
benign pulmonary nodules. In particular they were 
detected in 38 (69%) of 55 primary lung cancers and in 
9 (75%) of 12 lung metastases from extra-pulmonary 
cancers.  
 
Table 1. CTC/CTM and diagnoses in patients undergoing percutaneous CT-guided FNA or core biopsy. 
N. Patient Age, 
Sex 
FNAB Core Biopsy   CTC CTM Stage Final diagnosis 
1 81, M Squamous cell ca - 3 1 IIa Squamous cell ca 
2 69, F Adenocarcinoma - 2 3 pT1aN2IIIa Adenocarcinoma 
3 64, M Squamous cell ca - 12  Ia Squamous cell ca 
4 79, M Adenocarcinoma - 2 4 IV Adenocarcinoma 
5 79, F Adenocarcinoma - 8 2 IV Adenocarcinoma 
6 65, F Mtx (Squamous cell ca) - 1 5 - Mtx (Squamous cell ca Head & Neck) 
7 69, F Inflammatory cells Inflammation - - - Inflammation 
8 74, F Adenocarcinoma - 2 1 IV Adenocarcinoma 
9 66, M Adenocarcinoma Adenocarcinoma 8 2 IV Adenocarcinoma 
10 87, M Mtx (Urothelial ca) - - - - Mtx (Urothelial ca) 
11 74, M Squamous cell ca - 6 11 IIIa Squamous cell ca 
12 75, M Adenocarcinoma - 6 23 IV Adenocarcinoma 




13 67, M Adenocarcinoma - 6 2 pT1bN0Ia Adenocarcinoma 
14 83, M Mtx (Squamous cell ca) - 6 4 - Mtx (Squamous cell ca Head & Neck) 
15 74, M Inflammatory cells Inflammation - - - Inflammation 
16 79, F Adenocarcinoma - 4 3 IIa Adenocarcinoma 
17 74, M Amarthocondroma - - - - Amarthocondroma 
18 79, F Adenocarcinoma - 9 4 IIIa Adenocarcinoma 
19 82, F Adenocarcinoma Insufficient material - 1 IIIb Adenocarcinoma 
20 81, M Adenocarcinoma - 8 18 IV Adenocarcinoma 
21 64, F Mtx (Squamous cell ca) - - - - Mtx (Squamous cell ca Larynx) 
22 73, M Insufficient material - - - - Sarcoidosis 
23 75, M Squamous cell ca - 2 5 pT1aN0Ia Squamous cell ca 
24 71, M Adenocarcinoma - 5 9 IV Adenocarcinoma 
25 72, M Adenocarcinoma - 8 2 pT1bN0Ia Adenocarcinoma 
26 65, M Adenocarcinoma - - 2 pT1aN0Ia Adenocarcinoma 
27 75, M Squamous cell ca - 2 - IIIa Squamous cell ca 
28 67, M NSCLC NOS - - 3 IV NSCLC NOS 
29 57, F Adenocarcinoma - 5 1 IIIa Adenocarcinoma 
30 68, F Adenocarcinoma - 4 3 pT1aN0Ia Adenocarcinoma 
31 78, M Mtx (Intestinal Adenocarcinoma) - - - - Mtx (Colon 
Adenocarcinoma) 
32 70, F Adenocarcinoma - 4 - IV Adenocarcinoma 
33 80, M Insufficient material Insufficient material - 2 Ia Adenocarcinoma* 
34 83, M Adenocarcinoma - - 1 IV Adenocarcinoma 
35 72, M Adenocarcinoma - 5 10 pT1bN0Ia Adenocarcinoma 
36 83, F Adenocarcinoma - - 8 IIIa Adenocarcinoma 
37 75, M Mtx (Intestinal Adenocarcinoma) - 2 4 - Mtx (Colon Adenocarcinoma) 
38 74, F Adenocarcinoma - 4 1 IV Adenocarcinoma 
39 63, F Adenocarcinoma - - 1 Ia Adenocarcinoma 
40 73, F Adenocarcinoma Adenocarcinoma 10 3 IV Adenocarcinoma 
41 49, F Mtx (Breast ca) - 5 3  Mtx (Breast ca) 
42 81, M Adenocarcinoma - 3 1 Ia Adenocarcinoma 
43 75, M Inflammatory cells Abscess - - - Abscess 
44 69, M Adenocarcinoma Adenocarcinoma - 3 Ia Adenocarcinoma 
45 51, M Adenocarcinoma - 2 1 Ia Adenocarcinoma 
46 70, M Squamous cell ca - - - pT2bN0IIa Squamous cell ca 
47 71, M Mtx (neuroendocrine ca) - 5 3 - Mtx (Neuroendocrine ca) 
48 84, M Adenocarcinoma Adenocarcinoma - - IV Adenocarcinoma 
49 74, M Squamous cell ca - - - IV Squamous cell ca 
50 64, M Insufficient material - - - - Amarthocondroma 
51 74, F Squamous cell ca - - - IIIa Squamous cell ca 
52 76, F Adenocarcinoma - - - pT2aN0IIa Adenocarcinoma 
53 85, F Neuroendocrine malignant Neuroendocrine malignant - - IV-diffuse Neuroendocrine malignant 
54 65, M Adenocarcinoma - - - Ia Adenocarcinoma 
55 83, M Squamous cell ca - - - Ia Squamous cell ca 
56 62, F Adenocarcinoma - - - Ia Adenocarcinoma 
57 68, F Mtx (Breast ca) - 2 1 - Mtx (Breast ca) 
58 82, F Adenocarcinoma - - - Ib Adenocarcinoma 
59 76, M Adenocarcinoma - - - Ia Adenocarcinoma 
60 64, F Neuroendocrine tumor - - - pT1aN0Ia Typical carcinoid 
61 66, M Carcinoid Carcinoid - - pT1aN0Ia Typical carcinoid 
62 79, F Insufficient material Insufficient material 5 2 IV Adenocarcinoma* 
63 75, F Inconclusive Inconclusive 3 10 pT2bN1IIb Adenocarcinoma 
64 52, F Mtx (Intestinal adenocarcinoma) - - 4 - Mtx (Colon Adenocarcinoma) 
65 75, M SCLC - 6 5 - SCLC 
66 83, M NSCLC  Squamous cell ca - - IIIa Squamous cell ca 
67 29, M Amarthocondroma Amarthocondroma - - - Amarthocondroma 
68 72, F Adenocarcinoma - - - Ia Adenocarcinoma 
69 67, M Mtx (Pancreatic Adenocarcinoma) - 2 1 IV Mtx (Pancreas Adenocarcinoma) 
70 55, F Adenocarcinoma Adenocarcinoma - 5 Ib Adenocarcinoma 
71 85, F Squamous cell ca Squamous cell ca - - Ib Squamous cell ca 
72 68, F Inflammatory cells Inflammation - - - Inflammation 
73 79, M Mtx (intestinal Adenocarcinoma) Mtx (intestinal Adenocarcinoma) - 3 - Mtx (Colon adenocarcinoma) 
74 75, M Adenocarcinoma - - 10 Ib Adenocarcinoma 
75 51, M Squamous cell ca Squamous cell ca - - IIa Squamous cell ca 
Ca = carcinoma; FNAB = Fine Needle Aspiration Biopsy; Mtx = metastasis; NSCLC NOS = Non Small Cell Lung Cancer Not Otherwise Specified; SCLC = Small Cell Lung 
Carcinoma. * Diagnosis made with Trans-Bronchial Needle Aspiration biopsy. 
 
 





Figure 1: Results of CTC/CTM search and percutaneous FNA or core biopsy in 75 patients. 
 
Figure 2 (A-B): CTM in a case (number 63) of inconclusive FNA and core biopsy. (A) CT shows a consolidation in the left upper lobe with air bronchogram and 
small bronchiectases. (B) Filter (Hematoxylin and Eosin staining, original magnification x1,000) showing a CTM formed by more than 20 CTC with variably increased 
and irregularly shaped nuclei and multiple 8 µm pores of the filter appearing as black dots. Surgical pathology demonstrated a stage IIb adenocarcinoma. 
 
Overall sensitivity of CTC/CTM presence for 
malignancy was 70.1% (95%CI: 56.9-83.1%), specificity 
100%, PPV 100% and NPV 28.6% (95%CI: 11.9-45.3%). 
Remarkably, the presence of CTC/CTM 
anticipated the diagnosis of primary lung cancer in 3 
of 5 patients with non-diagnostic or inconclusive 
results of FNA or core biopsy, whereas CTC/CTM 
were not observed in 1 patient with sarcoidosis and 1 
with amarthocondroma. 
CTC/CTM were present in 17 of 29 (58%) 
patients with stage I-II and in 21 of 26 (80%) patients 
with stage III-IV primary lung cancer and in 31 of 38 
(81.5%) patients with adenocarcinoma and in 5 of 12 
(42%) patients with squamous cell carcinoma. 
Discussion 
Percutaneous CT-guided FNA and core biopsy 
are established diagnostic procedures for patients 
with peripheral nodule or mass of suspicious 
malignant nature [19]. The 93.3% diagnostic yield of 
FNA (with ROSE) and core biopsy in our series is in 
line with previous data [9, 19]. 
So far the diagnostic role of CTC/CTM search 
for lung cancer has been scarcely explored. One study 
evaluated CTC/CTM search with the ISET filtration 
method to anticipate lung cancer development in 




patients with chronic obstructive pulmonary disease 
who were followed up with CT until lung nodules 
were detected [20]. This clinical context is different 
from ours in which we investigated the capability of 
CTC/CTM to anticipate malignancy in patients with 
evidence of suspicious lung nodules or masses on CT. 
In particular while sensitivity is a major concern for 
studies addressing screening of lung cancer, 
specificity is the crucial feature requested to a 
diagnostic tool in patients with high suspicion of lung 
cancer. 
In the present study, we used the ScreenCell 
Cyto filtration method that allows isolation by cell 
size and does not involve any biological 
characterization of the putative CTC to preliminarily 
explore the predictive value for malignancy of 
detection of CTC/CTM in a prospective consecutive 
series of patients undergoing diagnostic FNA or core 
biopsy of pulmonary lesions of suspected malignant 
nature. Notably, in all our patients the blood sample 
for CTC search was taken before the diagnostic FNA 
or core biopsy by using the venous access that is 
routinely prepared in order to aid for therapeutic 
intervention in case of systemic adverse effects during 
or after the FNA or core biopsy procedure 
(hypotension, etc.). This time point for blood 
sampling enables us to get rid of the possibility that 
manipulation of lung cancer in diagnostic procedures 
including FNA or core biopsy determines delivery of 
CTC in the blood stream [11, 12]. 
There is growing evidence that CTM do not 
derive from CTC conglomeration in the blood stream 
and rather represent cell aggregates originating in the 
tumor and entering the vasculature, possibly as the 
result of the surface expression of specific molecules 
promoting cellular adhesion [21, 22]. CTM might be 
more capable of metastasizing as compared with 
single CTC [22]. Moreover, the presence and number 
of CTM is a poor prognostic factor, in particular for 
patients with small cell lung cancer [23, 24]. However, 
since we were interested here in the potential 
diagnostic predictive value rather than prognostic 
role of CTC and CTM, the present study considered 
their presence both separately and altogether.  
In prior studies evaluating possible contribute of 
presence of CTC or CTM in cases with putative 
malignant lesions of solid primary tumors of 
pancreas, stomach, breast and prostate, the overall 
sensitivity for malignant lesions ranged between 42 
and 86% [5-8], whereas specificity was higher and in 
the 91-100% range [5-8]. Using antibodies for 
detection of CTC (Veridex® LLC; NJ, USA), Maestro 
et al. [25] found 2 or more CTCs/7.5 mL in 31.5% of 
438 patients with several types of primary cancer 
(breast, colorectal, prostate) but in none of 106 healthy 
control subjects. The 62.3% of patients with metastatic 
disease had 2 or more CTCs/7.5 mL as compared to 
only 14.0% of those with localized disease. The 
presence of CTCs was correlated to stage in the three 
studied tumor types and no differences in the number 
of cells were found between them. 
When we considered the whole series of our 
patients we obtained a sensitivity of 70% and 
specificity of 100%. Sensitivity was 69% in primary 
lung cancers (58% in stage I-II lesions and 80% in 
stage III-IV lesions) and 75% in metastases. 
The 69% positivity of CTC/CTM in our series of 
55 primary lung cancers of different type and stage is 
substantially in line with the 46-80% CTC prevalence 
reported in previous series of early or advanced non 
small cell lung cancer [14, 16, 17, 26, 27]. 
Sensitivity, specificity and positive and negative 
predictive values in our series indicate that 
CTC/CTM presence in peripheral blood samples may 
be a highly specific but rather insensitive marker of 
the malignant nature of pulmonary lesions scheduled 
for percutaneous CT-guided biopsy. The reasons why 
CTC/CTM presence is detectable in most but not all 
cases of lung cancers and metastases, implying low 
sensitivity of the method [28], are not established. 
CTC/CTM detection may be influenced by several 
factors, including performance of the detection 
method, intermittent blood release of CTC from the 
primary tumor, and a lymphatic rather than blood 
tumor cell release.  
Lack of CTC/CTM in all our 8 patients with 
FNA or core biopsy diagnosed benign pathology may 
be of interest. In fact, although CTC or CTM usually 
do not occur in healthy subjects [25, 29], our data 
indicate a potential role of CTC search in the clinical 
setting. Circulating non-hematological cells (CNHCs) 
which can be misdiagnosed as CTC have been 
reported in patients without cancers, namely with 
benign thyroid, parathyroid and pancreas pathologies 
[29, 30]. However, application of cytomorphological 
criteria developed to characterize the malignant or 
non-malignant nature of CNHCs can solve the issue 
[4]. Obviously, data in larger cohorts of patients with 
benign pulmonary lesions are required to further 
assess specificity of CTC/CTM presence. 
In our opinion, also the data we obtained in the 5 
patients who had non-diagnostic or inconclusive 
results of percutaneous FNA or core biopsy are of 
note. In fact, they suggest that CTC/CTM presence 
can anticipate malignancy and may theoretically 
represent a useful clue in cases with non-diagnostic or 
inconclusive FNA or core biopsy. 
We recognize the following limitations of our 
study. First, CTC/CTM detection based on 
cytomorphometric criteria entails some operator 




dependence. However, the reported inter-operator 
variability for CTC identification using the 
cytomorphometric criteria we adopted is low [16] and 
filter visual assessment was performed in consensus 
by the cytopathologists. Second, CTC or CTM 
detection per se is certainly not sufficient for diagnostic 
purposes. In particular we did not address the 
capability of CTC/CTM characterization to 
differentiate between primary lung cancer and 
metastatic lung nodules from extra-pulmonary 
tissues, which is fundamental for diagnostic purposes. 
From this point of view, as immunocytochemistry in 
the FNA or core biopsy is capable to establish the 
primary or secondary nature of the lung malignant 
lesion, it can be anticipated that a similar phenotypic 
characterization of CTC/CTM with specific markers 
may overcome this limitation. Immunocytochemistry 
characterization of the CTC and CTM isolated with 
filtration is possible and represents a rapidly growing 
field [4, 7, 8, 31-34], but it was not performed here. 
Alternatively, genomic and expression analysis of 
CTC can be useful for such a purpose [2]. 
In conclusion, our preliminary data suggest that 
presently, due to the low sensitivity, the search of 
CTC/CTM cannot replace CT guided percutaneous 
FNA or core biopsy in the diagnostic work-up of 
patients with suspicious malignant lung lesions. 
However, the high specificity may as yet indicate a 
role in cases with non-diagnostic or inconclusive FNA 
or core biopsy results to be further investigated. 
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